Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 136 articles:
HTML format



Single Articles


    June 2022
  1. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    PubMed    


  2. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed     Abstract available


    May 2022
  3. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    PubMed    


  4. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    PubMed    


  5. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed     Abstract available


  6. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed     Abstract available


    April 2022
  7. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    PubMed    


  8. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    PubMed     Abstract available


  9. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    PubMed     Abstract available


  10. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    PubMed     Abstract available


    March 2022
  11. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    PubMed    


  12. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    PubMed     Abstract available


  13. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    


  14. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    PubMed     Abstract available


  15. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    PubMed     Abstract available


    February 2022
  16. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    PubMed     Abstract available


  17. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    PubMed     Abstract available


  18. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    PubMed    


  19. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    PubMed     Abstract available


  20. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    PubMed     Abstract available


  21. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    PubMed    


  22. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    PubMed     Abstract available


  23. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    PubMed     Abstract available


    January 2022
  24. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    PubMed     Abstract available


  25. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    PubMed     Abstract available


  26. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    PubMed     Abstract available


  27. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    PubMed     Abstract available


  28. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    PubMed     Abstract available


  29. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    PubMed     Abstract available


  30. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    PubMed    


  31. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    PubMed    


    December 2021
  32. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    PubMed     Abstract available


  33. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    PubMed    



  34. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    PubMed    


  35. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    PubMed    


  36. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    PubMed    


  37. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available


  38. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available


  39. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    PubMed    


  40. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    PubMed    


  41. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    PubMed    


  42. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    PubMed    


    November 2021
  43. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
    PubMed    


  44. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
    PubMed    


  45. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
    PubMed    


  46. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
    PubMed    


  47. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available


  48. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    PubMed     Abstract available


  49. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    PubMed     Abstract available


    October 2021
  50. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    PubMed     Abstract available


  51. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    PubMed     Abstract available


  52. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
    PubMed    


    September 2021
  53. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
    PubMed    


  54. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    PubMed     Abstract available


  55. WILDER-SMITH A, Desai S, Cravioto A, Nohynek H, et al
    Caution before fractionating COVID-19 vaccines.
    Nat Med. 2021 Sep 22. pii: 10.1038/s41591-021-01534.
    PubMed    


  56. CHOI A, Koch M, Wu K, Chu L, et al
    Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
    Nat Med. 2021 Sep 15. pii: 10.1038/s41591-021-01527.
    PubMed     Abstract available


  57. APOSTOLIDIS SA, Kakara M, Painter MM, Goel RR, et al
    Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Nat Med. 2021 Sep 14. pii: 10.1038/s41591-021-01507.
    PubMed     Abstract available


  58. DAGAN N, Barda N, Biron-Shental T, Makov-Assif M, et al
    Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
    Nat Med. 2021 Sep 7. pii: 10.1038/s41591-021-01490.
    PubMed     Abstract available


  59. SAVULESCU J, Pugh J, Wilkinson D
    Balancing incentives and disincentives for vaccination in a pandemic.
    Nat Med. 2021 Sep 6. pii: 10.1038/s41591-021-01466.
    PubMed    


  60. ONEKO M, Steinhardt LC, Yego R, Wiegand RE, et al
    Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
    Nat Med. 2021;27:1636-1645.
    PubMed     Abstract available


  61. KOUP RA, Donis RO, Gilbert PB, Li AW, et al
    A government-led effort to identify correlates of protection for COVID-19 vaccines.
    Nat Med. 2021;27:1493-1494.
    PubMed    


  62. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.
    PubMed    


    August 2021
  63. CHAGLA Z, Pai M
    COVID-19 boosters in rich nations will delay vaccines for all.
    Nat Med. 2021 Aug 31. pii: 10.1038/s41591-021-01494.
    PubMed    


    July 2021
  64. MEDEIROS-RIBEIRO AC, Aikawa NE, Saad CGS, Yuki EFN, et al
    Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
    Nat Med. 2021 Jul 30. pii: 10.1038/s41591-021-01469.
    PubMed     Abstract available


  65. DEMING ME, Lyke KE
    A 'mix and match' approach to SARS-CoV-2 vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01463.
    PubMed    


  66. SCHMIDT T, Klemis V, Schub D, Mihm J, et al
    Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01464.
    PubMed     Abstract available


  67. MACHINGAIDZE S, Wiysonge CS
    Understanding COVID-19 vaccine hesitancy.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.
    PubMed    


  68. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
    COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
    PubMed     Abstract available


  69. O'LEARY K
    Another COVID-19 vaccine to boost rollout.
    Nat Med. 2021 Jul 15. pii: 10.1038/d41591-021-00045.
    PubMed    


  70. BARROS-MARTINS J, Hammerschmidt SI, Cossmann A, Odak I, et al
    Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Nat Med. 2021 Jul 14. pii: 10.1038/s41591-021-01449.
    PubMed     Abstract available


  71. LOUBET P, Wittkop L, Tartour E, Parfait B, et al
    A French cohort for assessing COVID-19 vaccine responses in specific populations.
    Nat Med. 2021 Jul 12. pii: 10.1038/s41591-021-01435.
    PubMed    


  72. CHEMAITELLY H, Yassine HM, Benslimane FM, Al Khatib HA, et al
    mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Nat Med. 2021 Jul 9. pii: 10.1038/s41591-021-01446.
    PubMed     Abstract available


  73. KRAMMER F
    A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
    Nat Med. 2021 Jul 8. pii: 10.1038/s41591-021-01432.
    PubMed    


  74. COWLING BJ, Lim WW, Cobey S
    Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01440.
    PubMed    


  75. BARBERIA LG, Costa SF, Sabino EC
    Brazil needs a coordinated and cooperative approach to tackle COVID-19.
    Nat Med. 2021;27:1133-1134.
    PubMed    


  76. ALOBO M
    Strengthened health systems are needed to tackle COVID-19 in Africa.
    Nat Med. 2021;27:1126-1127.
    PubMed    


  77. SINGH J, Rahman SA, Ehtesham NZ, Hira S, et al
    SARS-CoV-2 variants of concern are emerging in India.
    Nat Med. 2021;27:1131-1133.
    PubMed    


  78. KHOURY DS, Cromer D, Reynaldi A, Schlub TE, et al
    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:1205-1211.
    PubMed     Abstract available


  79. LUCAS C, Klein J, Sundaram ME, Liu F, et al
    Delayed production of neutralizing antibodies correlates with fatal COVID-19.
    Nat Med. 2021;27:1178-1186.
    PubMed     Abstract available


    June 2021
  80. O'LEARY K
    Building a pandemic-proof vaccine.
    Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.
    PubMed    


  81. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    PubMed     Abstract available


  82. KUSTIN T, Harel N, Finkel U, Perchik S, et al
    Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Nat Med. 2021 Jun 14. pii: 10.1038/s41591-021-01413.
    PubMed     Abstract available


  83. MILMAN O, Yelin I, Aharony N, Katz R, et al
    Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
    Nat Med. 2021 Jun 10. pii: 10.1038/s41591-021-01407.
    PubMed     Abstract available


  84. PRITCHARD E, Matthews PC, Stoesser N, Eyre DW, et al
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01410.
    PubMed     Abstract available


  85. PISHKO AM, Bussel JB, Cines DB
    COVID-19 vaccination and immune thrombocytopenia.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01419.
    PubMed    


  86. SIMPSON CR, Shi T, Vasileiou E, Katikireddi SV, et al
    First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01408.
    PubMed     Abstract available


  87. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    PubMed     Abstract available



  88. To curb COVID-19, global health must go local.
    Nat Med. 2021;27:929.
    PubMed    


    May 2021
  89. MAY M
    After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
    Nat Med. 2021 May 31. pii: 10.1038/s41591-021-01393.
    PubMed    


  90. AU L, Fendler A, Shepherd STC, Rzeniewicz K, et al
    Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Nat Med. 2021 May 26. pii: 10.1038/s41591-021-01387.
    PubMed     Abstract available


  91. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2021 May 21. pii: 10.1038/s41591-021-01363.
    PubMed    


  92. SCHMIDT H, Weintraub R, Williams MA, Miller K, et al
    Equitable allocation of COVID-19 vaccines in the United States.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01379.
    PubMed     Abstract available


  93. WARD BJ, Gobeil P, Seguin A, Atkins J, et al
    Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01370.
    PubMed     Abstract available


  94. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2021 May 6. pii: 10.1038/s41591-021-01372.
    PubMed    


  95. SINGH JA, Kochhar S, Wolff J
    Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 May 4. pii: 10.1038/s41591-021-01360.
    PubMed    


  96. ANDREANO E, Rappuoli R
    SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
    Nat Med. 2021;27:759-761.
    PubMed    


  97. OTU A, Agogo E, Ebenso B
    Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Nat Med. 2021;27:744-745.
    PubMed    


    April 2021

  98. COVID-19 vaccine and blood clotting.
    Nat Med. 2021 Apr 29. pii: 10.1038/d41591-021-00025.
    PubMed    


  99. DAL-RE R, Orenstein W, Caplan AL
    Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Nat Med. 2021 Apr 26. pii: 10.1038/s41591-021-01338.
    PubMed    


  100. LI J, Hui A, Zhang X, Yang Y, et al
    Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Nat Med. 2021 Apr 22. pii: 10.1038/s41591-021-01330.
    PubMed     Abstract available


  101. ZARD M, Lau LS, Bowser DM, Fouad FM, et al
    Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations.
    Nat Med. 2021 Apr 19. pii: 10.1038/s41591-021-01328.
    PubMed    


  102. GIORDANO G, Colaneri M, Di Filippo A, Blanchini F, et al
    Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Nat Med. 2021 Apr 16. pii: 10.1038/s41591-021-01334.
    PubMed     Abstract available


  103. BAUSCH DG
    The need for a new strategy for Ebola vaccination.
    Nat Med. 2021 Apr 5. pii: 10.1038/s41591-021-01313.
    PubMed    


  104. EBINGER JE, Fert-Bober J, Printsev I, Wu M, et al
    Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Nat Med. 2021 Apr 1. pii: 10.1038/s41591-021-01325.
    PubMed     Abstract available


  105. EXCLER JL, Saville M, Berkley S, Kim JH, et al
    Vaccine development for emerging infectious diseases.
    Nat Med. 2021;27:591-600.
    PubMed     Abstract available


  106. CHEN RE, Zhang X, Case JB, Winkler ES, et al
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Nat Med. 2021;27:717-726.
    PubMed     Abstract available


  107. WIBMER CK, Ayres F, Hermanus T, Madzivhandila M, et al
    SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Nat Med. 2021;27:622-625.
    PubMed     Abstract available


  108. BURIONI R, Topol EJ
    Assessing the human immune response to SARS-CoV-2 variants.
    Nat Med. 2021;27:571-572.
    PubMed    


  109. KINGANDA-LUSAMAKI E, Black A, Mukadi DB, Hadfield J, et al
    Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.
    Nat Med. 2021;27:710-716.
    PubMed     Abstract available


    March 2021
  110. CLARKE PM, Roope LSJ, Loewen PJ, Bonnefon JF, et al
    Public opinion on global rollout of COVID-19 vaccines.
    Nat Med. 2021 Mar 30. pii: 10.1038/s41591-021-01322.
    PubMed    


  111. LEVINE-TIEFENBRUN M, Yelin I, Katz R, Herzel E, et al
    Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Nat Med. 2021 Mar 29. pii: 10.1038/s41591-021-01316.
    PubMed     Abstract available


  112. PLANAS D, Bruel T, Grzelak L, Guivel-Benhassine F, et al
    Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Nat Med. 2021 Mar 26. pii: 10.1038/s41591-021-01318.
    PubMed     Abstract available


  113. SARGENT J
    Vaccines reduce childhood mortality.
    Nat Med. 2021 Mar 18. pii: 10.1038/d41591-021-00014.
    PubMed    


  114. SINGH JA, Kochhar S, Wolff J
    Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 Mar 16. pii: 10.1038/s41591-021-01299.
    PubMed    


  115. EKSTROM AM, Berggren C, Tomson G, Gostin LO, et al
    The battle for COVID-19 vaccines highlights the need for a new global governance mechanism.
    Nat Med. 2021 Mar 11. pii: 10.1038/s41591-021-01288.
    PubMed    


  116. MARHOLD K, Fell J
    Electronic vaccination certificates: avoiding a repeat of the contact-tracing 'format wars'.
    Nat Med. 2021 Mar 4. pii: 10.1038/s41591-021-01286.
    PubMed    


  117. DURRHEIM DN, Andrus JK, Tabassum S, Bashour H, et al
    A dangerous measles future looms beyond the COVID-19 pandemic.
    Nat Med. 2021;27:360-361.
    PubMed    


  118. AHMED I
    Dismantling the anti-vaxx industry.
    Nat Med. 2021;27:366.
    PubMed    


    February 2021
  119. VAN DER VELDT AAM, Oosting SF, Dingemans AC, Fehrmann RSN, et al
    COVID-19 vaccination: the VOICE for patients with cancer.
    Nat Med. 2021 Feb 15. pii: 10.1038/s41591-021-01240.
    PubMed    


  120. XIE X, Liu Y, Liu J, Zhang X, et al
    Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-021-01270.
    PubMed     Abstract available



  121. COVID-19 vaccines: acting on the evidence.
    Nat Med. 2021 Feb 4. pii: 10.1038/s41591-021-01261.
    PubMed    


  122. STOWER H
    A functioning vaccine in mouse models of multiple sclerosis.
    Nat Med. 2021 Feb 1. pii: 10.1038/d41591-021-00006.
    PubMed    


    January 2021
  123. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available


  124. KIM JH, Marks F, Clemens JD
    Looking beyond COVID-19 vaccine phase 3 trials.
    Nat Med. 2021 Jan 19. pii: 10.1038/s41591-021-01230.
    PubMed     Abstract available


  125. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2021 Jan 11. pii: 10.1038/s41591-020-01226.
    PubMed    


  126. KAMPMANN B
    Women and children last? Shaking up exclusion criteria for vaccine trials.
    Nat Med. 2021;27:8.
    PubMed    


  127. WAGAR LE, Salahudeen A, Constantz CM, Wendel BS, et al
    Modeling human adaptive immune responses with tonsil organoids.
    Nat Med. 2021;27:125-135.
    PubMed     Abstract available


  128. BURTON DR, Topol EJ
    Toward superhuman SARS-CoV-2 immunity?
    Nat Med. 2021;27:5-6.
    PubMed    


    December 2020
  129. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01194.
    PubMed     Abstract available


  130. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01179.
    PubMed     Abstract available


  131. NACHBAGAUER R, Feser J, Naficy A, Bernstein DI, et al
    A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nat Med. 2020 Dec 7. pii: 10.1038/s41591-020-1118.
    PubMed     Abstract available


  132. CARVALHO T
    Vaccines in the fast lane.
    Nat Med. 2020;26:1807.
    PubMed    


    November 2020
  133. GALLAGHER ME, Sieben AJ, Nelson KN, Kraay ANM, et al
    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Nat Med. 2020 Nov 23. pii: 10.1038/s41591-020-01172.
    PubMed    


    October 2020
  134. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2020 Oct 20. pii: 10.1038/s41591-020-1124.
    PubMed     Abstract available



  135. Scientists, keep an open line of communication with the public.
    Nat Med. 2020;26:1495.
    PubMed    


    August 2020
  136. PARK JK, Xiao Y, Ramuta MD, Rosas LA, et al
    Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Nat Med. 2020;26:1240-1246.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: